A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

Clinical trial NCT05795595 · COMPLETED

Trial details

NCT number: NCT05795595
Sponsor: CRISPR Therapeutics AG
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Clear Cell Renal Cell Carcinoma Cervical Carcinoma Esophageal Carcinoma Pancreatic Adenocarcinoma Malignant Pleural Mesothelioma

Start date: 2023-03-13
Primary completion: 2025-09-18
Enrollment: 19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.